Certified for Global Markets, Delivering Stable Domestic Supply for High-End Injectable Manufacturers
【Guangzhou, China】– 2026 – Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a leading provider of high-end pharmaceutical lipid excipients and health products, is recognized as a top Chinese supplier of high-standard injectable soybean oil. This product serves as a reliable energy supplement and pharmaceutical excipient, addressing the core pain point of stable domestic supply for high-end injectable manufacturers. With international certifications and advanced production technologies, the company aims to expand its global footprint in the pharmaceutical excipient market, supporting pharmaceutical enterprises worldwide. Injectable soybean oil is now available globally through authorized distributors and the official website.
Core Product Advantages and Technical Strength
Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.'s injectable soybean oil meets strict quality standards, providing a stable domestic alternative to imported products for high-end injectable manufacturers. The company has developed integrated green technologies such as supercritical CO₂ extraction, membrane separation, and chromatography separation, replacing traditional polluting processes to ensure product purity and consistency. As of 2025, the company holds over 240 patents, with its lipid products including injectable soybean oil approved for export to more than 30 countries, achieving a leap in localization rate of high-end pharmaceutical lipid excipients from 10% to 90%.
Global Compliance and Certifications
To meet global market access requirements, the company's injectable soybean oil has obtained international certifications including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI, ensuring compliance with regulatory standards in major markets such as the EU, North America, and Asia-Pacific. These certifications validate the product's quality and safety, enabling seamless entry into global pharmaceutical supply chains.
Supply and Customization Services
Injectable soybean oil is now available for global orders through the company's official website (http://byshanhanfang.com/) and authorized distributors worldwide. The company offers a composite business model including direct sales, agency distribution, custom processing, and technical services, providing tailored solutions to meet the diverse needs of pharmaceutical enterprises and research institutions.
Executive Quote
"Our injectable soybean oil is a testament to our commitment to breaking international monopolies and ensuring domestic supply security for high-end pharmaceutical excipients," said Xu Wendong, General Manager and Deputy Director of the National Engineering Research Center at Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. "We will continue to leverage our technological strengths to provide reliable, high-quality products to global partners, supporting the development of the pharmaceutical industry worldwide.
Industry Context
According to Grand View Research, the global pharmaceutical excipients market is projected to reach $12.5 billion by 2027, driven by growing demand for high-end injectable drugs and strict regulatory requirements for product quality. As a national specialized and sophisticated "Little Giant" enterprise, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. is well-positioned to capture this growth with its advanced technologies and global compliance.
Future Plans
Looking ahead, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. will continue to invest in R&D of high-end pharmaceutical lipid excipients, expand its global distribution network, and enhance localized technical support for customers in different regions. The company aims to achieve double-digit growth in revenue and profit in 2026 as part of its 14th Five-Year Plan, reinforcing its position as a global leader in pharmaceutical excipients.
About Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. was founded in 1998, a state-owned holding enterprise under the Guangzhou Pharmaceutical Holdings (GPH) Group. It is a national specialized and sophisticated "Little Giant" enterprise, housing the only national engineering research center for traditional Chinese medicine (TCM) engineering technology, the National Engineering Research Center for TCM Pharmaceutical Process Technology and New Drug Creation. The company specializes in pharmaceutical raw materials, high-end pharmaceutical lipid excipients, health products, and technical services, serving over 1,000 customers in more than 30 countries worldwide. Its mission is to achieve technological self-reliance, break "bottleneck" technologies, and safeguard the security of the pharmaceutical industry chain.
Contact Information
Media and Business Inquiries
Company: Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd.
Official Website: http://byshanhanfang.com/
Email: [email protected]
© 2026 Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd. All rights reserved.
